HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norov... HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Show more
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus...
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -6.82926829268 | 2.05 | 2.08 | 1.905 | 275816 | 1.96852751 | CS |
4 | 0.05 | 2.68817204301 | 1.86 | 2.15 | 1.83 | 346935 | 1.9773492 | CS |
12 | 0.04 | 2.13903743316 | 1.87 | 2.15 | 1.78 | 242563 | 1.95314879 | CS |
26 | 0.13 | 7.30337078652 | 1.78 | 2.15 | 1.58 | 355325 | 1.8558891 | CS |
52 | -12.72 | -86.9446343131 | 14.63 | 20.22 | 1.55 | 419788 | 4.1485204 | CS |
156 | -16.85 | -89.8187633262 | 18.76 | 24.42 | 1.55 | 216935 | 7.2147817 | CS |
260 | -16.85 | -89.8187633262 | 18.76 | 24.42 | 1.55 | 216935 | 7.2147817 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.